Shares of Anavex Life Sciences (AVXL) surged 5.25% in the pre-market trading session on Friday. This substantial pre-market gain follows an analyst action from HC Wainwright.
According to the news, HC Wainwright has adjusted its price target on Anavex Life Sciences from $40 to $42 while maintaining a "Buy" rating on the stock. The increased price target suggests that the analyst firm expects further upside potential for Anavex Life Sciences shares.
Analyst price target updates often act as a catalyst for stock price movements, as they reflect the analyst's assessment of a company's future prospects and valuation. A higher price target generally implies more bullish sentiment on the stock, leading to increased investor demand and a subsequent rise in the share price.